VAXMED Presents Vaccine Breakthrough at Panel Discussion with Global Vaccine Companies

Adelaide, Australia, 26 January 2023

The Adelaide-based company VAXMED is presenting its new vaccines at the Global Summit for Medical Biotechnology in Riyadh, Saudi Arabia, today. VAXMED is joined on the panel by Moderna Inc, USA; SK Bioscience and Cytiva Sweden and will invite discussions from the audience, including Pfizer, AstraZeneca, Novartis, Bayer AG, and J&J. This is the first time the global community will be briefed on VAXMED’s new vaccines and technologies. The company uses complex, proprietary computer algorithms to design highly effective vaccines and enable their development at an unprecedented speed. All vaccines are fully synthetic and designed to provide long-lasting immunity in a single immunisation and, at the same time, broad-spectrum cover against multiple virus strains or infectious diseases. In parallel, VAXMED is developing a proprietary manufacturing technology to produce 100s of millions of doses from each batch run in a matter of weeks.

Unlike most other vaccines, the VAXMED vaccines do not require consistent cold storage and temperature control from manufacture to the point of use. They can be stored at room temperature and when freeze-dried for many years. The technology synVAX, which stands for ‘synthetic vaccines,’ is highly stable DNA encapsulated in proteins in a natural self-assembly process, in a single manufacturing step. DNA is much more stable than mRNA and can deliver a large payload of vaccine antigens. The vaccines do not contain any adjuvants, additives, or stabilisers, and they do not replicate in the human body, a unique and essential safety feature. VAXMED has, in under one year, designed and synthesised five broad-spectrum vaccines. They include a vaccine covering multiple coronavirus strains and their variants; an Influenza A+B vaccine intended to replace the annual flu shot; a Respiratory Syncytial Virus (RSV) vaccine covering A and B subtypes; a Dual Staphylococcus and Pseudomonas Vaccine to prevent bacterial infections; and a veterinary vaccine against African Swine Fever.

“Our synVAX technology was evaluated by an independent panel of global vaccine experts and judged to be highly competitive among all technologies in terms of vaccine efficacy, potential safety, and scale of manufacturing” said Dr Paul Howley, Co-Founder and CEO. Dr Jurgen Michaelis, Co-Founder and Executive Chairman: “We have combined in our vaccines the best technologies and features available globally. This breakthrough has led to strong financial backing by Private Equity Gateway Group with offices in Australia, Hong Kong, Kuala Lumpur, Jakarta, and London.” When asked about the company’s goals: “We aim to complete preclinical development this year, including toxicology studies, conduct human Phase I clinical trials in 2024, followed by vaccines challenge trials in human volunteers in the UK in the same year. This should provide sufficient confidence to aspire for a listing on a major stock exchange shortly after.” “VAXMED’s aim is not to chase virus variants and catch up with modified vaccines, we aim to be ahead of the virus, slowing down mutations and creating roadblocks for new variants” he said.

Contact:

Dr Jurgen Michaelis

E: jurgen.michaelis@vaxmed.com.au

www.vaxmed.com.au